ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) - Pipeline Insight, 2020

Publisher Name :
Date: 24-Sep-2020
No. of pages: 75
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's, "ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) - Pipeline Insight, 2020," report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in ALK-positive Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

- Global coverage

ALK-positive Non-Small Cell Lung Cancer Understanding

ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC): Overview

ALK-positive lung cancer is a non-small cell lung cancer (NSCLC) that harbors a mutation in a gene called anaplastic lymphoma kinase (ALK). More precisely, it's a gene rearrangement—a fusion of ALK and another gene, echinoderm microtubule-associated protein-like 4 (EML4). This abnormal fusion causes cell enzymes (proteins) to send signals to mutated cancer cells telling them to divide and multiply more quickly than usual, which spreads the disease.

Discovered in 2007, "ALK-positive" refers to the rearrangement of the EML4 gene and the ALK (anaplastic lymphoma kinase) gene in DNA, resulting in a fusion oncogene EML4-ALK. An oncogene is a gene that is a mutated and may cause cancer cells.

Symptoms

Symptoms of lung cancer that are in the chest:

- Coughing, especially if it persists or becomes intense

- Pain in the chest, shoulder, or back unrelated to pain from coughing

- A change in color or volume of sputum

- Shortness of breath

- Changes in the voice or being hoarse

- Harsh sounds with each breath (stridor)

- Recurrent lung problems, such as bronchitis or pneumonia

- Coughing up phlegm or mucus, especially if it is tinged with blood

- Coughing up blood

Diagnosis

Anaplastic Lymphocyte Kinase is currently diagnosed by genetic testing, known as molecular testing, of a sample. Most doctors use a test called FISH (fluorescence in situ hybridization). In the United States, FISH, IHC, and NGS are approved companion diagnostic tests to identify Anaplastic Lymphocyte Kinase -positive NSCLC. In Europe, IHC is widely used to detect ALK. To obtain a sample, it is necessary to undergo a biopsy, typically through a needle biopsy or a small surgical procedure. We recommend going to an expert for this procedure, as it can be a challenging procedure.

Treatment

Crizotinib has become a reference treatment for Anaplastic Lymphocyte Kinase + NSCLC patients, and a promising treatment for tumours harbouring MET amplification and ROS1 aberrations. Unfortunately, many patients develop acquired resistance during the first year of treatment and its efficacy is limited in CNS disease. Strategies are urgently needed to overcome inherent and acquired resistance to ALK inhibition.

ALK-positive Non-Small Cell Lung Cancer Emerging Drugs Chapters

This segment of the ALK-positive Non-Small Cell Lung Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Anaplastic Lymphocyte Kinase -positive Non-Small Cell Lung Cancer Emerging Drugs

- Ensartinib: Betta Pharmaceuticals/Xcovery

Ensartinib is a potential best-in-class compound for the first-line treatment of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Ensartinib has shown promising clinical activity in patients with ALK-positive NSCLC in a phase 1/2 trial. A single-arm phase 2 trial of ensartinib as second-line treatment for patients with ALK-positive NSCLC previously treated with crizotinib has been completed in 156 Chinese patients, and a New Drug Application has been filed in China. An ensartinib global first-line phase 3 registration trial vs crizotinib is ongoing.

- TQ-B3139 - Chia Tai Tianqing Pharmaceutical Group

TQ-B3139 is an orally available, small molecule inhibitor of the receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and hepatocyte growth factor receptor (c-Met; HGFR), with potential antineoplastic activity. Upon oral administration, TQ-B3139 binds to and inhibits the activity of ALK and c-Met, which leads to the disruption of ALK- and c-Met-mediated signaling and the inhibition of cell growth in ALK- and c-Met-expressing tumor cells. ALK and c-Met, overexpressed or mutated in many tumor cell types, play key roles in tumor cell proliferation, survival, invasion and metastasis.

Further product details are provided in the report……..

ALK-positive Non-Small Cell Lung Cancer: Therapeutic Assessment

This segment of the report provides insights about the different ALK-positive Non-Small Cell Lung Cancer drugs segregated based on following parameters that define the scope of the report, such as:

- Major Players in ALK-positive Non-Small Cell Lung Cancer

There are approx. 30+ key companies which are developing the therapies for ALK-positive Non-Small Cell Lung Cancer. The companies which have their ALK-positive Non-Small Cell Lung Cancer drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Betta Pharmaceuticals/Xcovery, Chia Tai Tianqing Pharmaceutical Group, Merck, Pfizer etc.

Phases

DelveInsight's report covers around 30+ products under different phases of clinical development like

- Mid-stage products (Phase II and Phase I/II)

- Early-stage products (Phase I/II and Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

- Route of Administration

ALK-positive Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Oral

- Intramuscular

- Intratumoral

- Intravenous

- Molecule Type

Products have been categorized under various Molecule types such as

- Gene therapies

- Bispecific antibodies

- Immunotherapies

- Monoclonal antibodies

- Small molecules

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

ALK-positive Non-Small Cell Lung Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses ALK-positive Non-Small Cell Lung Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ALK-positive Non-Small Cell Lung Cancer drugs.

Report Highlights

- The companies and academics are working to assess challenges and seek opportunities that could influence ALK-positive Non-Small Cell Lung Cancer R&D. The therapies under development are focused on novel approaches to treat/improve ALK-positive Non-Small Cell Lung Cancer.

- August 2020: Ensartinib Improves Progression-Free Survival in Patients with ALK-Positive NSCLC

Treatment with ensartinib induced longer progression-free survival, compared with Xalkori (crizotinib) in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), according to new clinical trial data presented at International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer Virtual Presidential Symposium.

ALK-positive Non-Small Cell Lung Cancer Report Insights

- ALK-positive Non-Small Cell Lung Cancer Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

ALK-positive Non-Small Cell Lung Cancer Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing ALK-positive Non-Small Cell Lung Cancer drugs?

- How many ALK-positive Non-Small Cell Lung Cancer drugs are developed by each company?

- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of ALK-positive Non-Small Cell Lung Cancer?

- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the ALK-positive Non-Small Cell Lung Cancer therapeutics?

- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

- What are the clinical studies going on for ALK-positive Non-Small Cell Lung Cancer and their status?

- What are the key designations that have been granted to the emerging drugs?

Key Players

- GlaxoSmithKline

- Novartis

- AstraZeneca

- Pfizer Inc.

- F. Hoffmann-La Roche Ltd.

- Merck

- Suzhou Zelgen Biopharmaceuticals Co.,Ltd

- Ariad Pharmaceutica

- Takeda

- Chia Tai Tianqing Pharmaceutical Group

- Akeso

Key Products

- Ensartinib

- TQ B3139

- WX-0593

- M7824

ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) - Pipeline Insight, 2020

Table of Contents

Introduction
Executive Summary
ALK-positive Non-Small Cell Lung Cancer: Overview
* Causes
* Mechanism of Action
* Signs and Symptoms
* Diagnosis
* Disease Management
Pipeline Therapeutics
* Comparative Analysis
Therapeutic Assessment
* Assessment by Product Type
* Assessment by Stage and Product Type
* Assessment by Route of Administration
* Assessment by Stage and Route of Administration
* Assessment by Molecule Type
* Assessment by Stage and Molecule Type
ALK-positive Non-Small Cell Lung Cancer - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
* ALK-positive Non-Small Cell Lung Cancer companies' collaborations, Licensing, Acquisition -Deal Value Trends
ALK-positive Non-Small Cell Lung Cancer Collaboration Deals
* Company-Company Collaborations (Licensing / Partnering) Analysis
* Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
* Comparative Analysis
Ensartinib: Betta Pharmaceuticals/Xcovery
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
* Comparative Analysis
Bintrafusp alfa: EMD Serono/GlaxoSmithKline/Merck
* Product Description
* Research and Development
* Product Development Activities
Early Stage Products (Phase I)
* Comparative Analysis
PLB1003: Beijing Pearl Biotechnology Limited Liability Company
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
* Comparative Analysis
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
* Comparative Analysis
ALK-positive Non-Small Cell Lung Cancer Key Companies
ALK-positive Non-Small Cell Lung Cancer Key Products
ALK-positive Non-Small Cell Lung Cancer- Unmet Needs
ALK-positive Non-Small Cell Lung Cancer- Market Drivers and Barriers
ALK-positive Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
ALK-positive Non-Small Cell Lung Cancer Analyst Views
ALK-positive Non-Small Cell Lung Cancer Key Companies
Appendix

List of Tables

Table 1 Total Products for ALK-positive Non-Small Cell Lung Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for ALK-positive Non-Small Cell Lung Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures

Figure 1 Total Products for ALK-positive Non-Small Cell Lung Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
  • Global Lenvatinib Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 130
    According to this study, over the next five years the Lenvatinib market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Lenvatinib business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Lenvatinib market by product type, application, key......
  • Global Levoxyl Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 159
    According to this study, over the next five years the Levoxyl market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Levoxyl business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Levoxyl market by product type, application, key manufact......
  • Global Emergency Contraceptive Pills Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 159
    According to this study, over the next five years the Emergency Contraceptive Pills market will register a 3.2%% CAGR in terms of revenue, the global market size will reach $ 543.7 million by 2025, from $ 478.7 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Emergency Contraceptive Pills business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Emerge......
  • Global Trichomonas Rapid Testing Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 134
    According to this study, over the next five years the Trichomonas Rapid Testing market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Trichomonas Rapid Testing business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Trichomonas Rapid Tes......
  • Global Topical Excipients Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 132
    According to this study, over the next five years the Topical Excipients market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Topical Excipients business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Topical Excipients market by produc......
  • Global Topical Antibiotic Pharmaceuticals Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 135
    According to this study, over the next five years the Topical Antibiotic Pharmaceuticals market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Topical Antibiotic Pharmaceuticals business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Top......
  • Global Tissue-Replacement Products Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 136
    According to this study, over the next five years the Tissue-Replacement Products market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Tissue-Replacement Products business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Tissue-Replacemen......
  • Global Tissue Glue and Bio-adhesive Sealants Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 139
    According to this study, over the next five years the Tissue Glue and Bio-adhesive Sealants market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Tissue Glue and Bio-adhesive Sealants business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities ......
  • Global Tissue Culture Reagents Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 135
    According to this study, over the next five years the Tissue Culture Reagents market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Tissue Culture Reagents business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Tissue Culture Reagents m......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs